Research
Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.
Neuropharmacology – November 01, 2024
Summary
A groundbreaking discovery shows that ketamine's long-lasting antidepressant effects depend on how the liver processes it. When researchers blocked certain liver enzymes with fluconazole, ketamine's mood-lifting benefits disappeared. The key lies in hydroxynorketamine, a compound created when the body breaks down ketamine. This metabolite increases GABA levels in brain regions controlling mood, suggesting that ketamine's transformation in the body is crucial for its antidepressant properties.
Abstract
(R,S)-ketamine (ketamine) has rapid and sustained antidepressant (AD) efficacy at sub-anesthetic doses in depressed patients. A metabolite of ketam...
Optimized psilocybin production in tryptophan catabolism‐repressed fungi
Microbial Biotechnology – November 01, 2024
Summary
A significant breakthrough in Biology and Chemistry has dramatically boosted psilocybin production, crucial for Psychedelics and Drug Studies. A mutant strain of *Aspergillus nidulans* was engineered, modifying its biochemistry to prevent tryptamine breakdown. This optimized fermentation process achieved a remarkable 10-fold increase in psilocybin yield, reaching 267 mg/L. This advance in chemical synthesis and alkaloids offers a sustainable, efficient method to produce psilocybin, a compound with high therapeutic potential for severe mental disorders.
Abstract
Abstract The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental diso...
FDA Denies Approval of MDMA-Assisted Therapy for PTSD.
The American journal of nursing – November 01, 2024
Summary
Despite promising Phase 3 trials, regulators declined to approve MDMA-assisted psychotherapy for PTSD treatment, citing safety concerns and methodological issues in clinical studies. The decision impacts thousands of veterans and trauma survivors who showed significant symptom improvement in controlled therapeutic settings. Officials requested additional safety data and stricter protocols before reconsideration.
Abstract
The agency cited potential dangers and flaws in research methodology.
Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.
Journal of psychiatric research – November 01, 2024
Summary
A natural compound found in milk thistle shows promise in treating psychosis and schizophrenia-like symptoms. The plant-based antipsychotic, silymarin, effectively prevented and reversed behavioral changes in mice by reducing neuroinflammation and restoring brain chemistry balance. Unlike traditional medications, it improved both positive and negative symptoms without serious side effects, marking a potential breakthrough in neuropharmacology.
Abstract
Neurochemical dysregulations resulting from N-methyl-D-aspartate hypofunction (NMDA), are exacerbated by neuroimmune and oxidative stress and are k...
Disrupted Human-Dog Interbrain Neural Coupling in Autism-Associated Shank3 Mutant Dogs.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) – November 01, 2024
Summary
Dogs and humans can synchronize their brain activity during bonding moments like petting and eye contact. Scientists found that this neural connection grows stronger as relationships deepen. In dogs with Shank3 mutations linked to autism spectrum disorders, this brain synchronization is disrupted. Remarkably, treatment with LSD restored normal brain coupling and social attention in affected dogs.
Abstract
Dogs interact with humans effectively and intimately. However, the neural underpinnings for such interspecies social communication are not understo...
KETAMINE: Neural- and network-level changes.
Neuroscience – November 01, 2024
Summary
Ketamine's remarkable ability to reshape brain connectivity offers new hope for treating mental health conditions. This groundbreaking research reveals how ketamine enhances neuroplasticity by promoting hyperconnectivity between brain regions and fine-tuning neural responses. The drug increases neural synchrony across brain networks while reducing firing variability, creating more robust connections between neurons. These changes in brain circuitry help explain ketamine's powerful therapeutic effects and its potential to rapidly improve mood disorders.
Abstract
Ketamine is a widely used clinical drug that has several functional and clinical applications, including its use as an anaesthetic, analgesic, anti...
The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment.
Molecular genetics and metabolism – November 01, 2024
Summary
A surprising shift in understanding Nonketotic hyperglycinemia's pathophysiology is emerging. While excess glycine was once thought to overactivate brain receptors, leading to trials with Dextromethorphan or Ketamine, new insights reveal a crucial activator is actually *decreased*. This challenges the initial hypothesis, as clinical evidence hasn't shown these drugs provide added benefit. A critical reevaluation of Dextromethorphan and Ketamine's systematic use is vital for optimal patient care.
Abstract
The recognition of glycine as an endogenous ligand at the allosteric activation site of the NMDA-type glutamatergic receptor led to the assumption ...
How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety?
AMA journal of ethics – November 01, 2024
Summary
As psychedelic therapy gains mainstream acceptance, ketamine clinics offer valuable lessons for safely expanding access. Research shows that balancing medical oversight with personal autonomy is key - strict protocols protect vulnerable patients while avoiding over-medicalization. The solution involves clear guidelines distinguishing between clinical treatment and wellness applications, with appropriate safeguards for each path.
Abstract
Psychedelics have long been used by individuals seeking peace and a sense of wellness. This article examines widespread adoption of ketamine as a p...
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkable findings from initial clinical trials suggested a novel approach for severe PTSD. Researchers explored how MDMA, when combined with specialized psychotherapy, could significantly reduce symptoms. A comprehensive analysis of six early-stage randomized controlled trials revealed positive results, demonstrating substantial improvement in participants' well-being. This innovative treatment strategy provided a strong rationale for advancing to larger-scale clinical trials as an effective PTSD treatment.
Abstract
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six p...
Effects of Small-Dose Esketamine on Postoperative Analgaesia and Sleep Quality in Patients with Total Hip Replacement.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP – November 01, 2024
Summary
A promising alternative to traditional pain management after hip replacement has emerged: small doses of esketamine provide better pain relief with fewer complications than standard fentanyl treatment. Patients receiving esketamine needed pain medication later and required fewer doses overall. While sleep quality remained similar between treatments, esketamine patients avoided common issues like urinary retention that affected fentanyl users.
Abstract
To determine the effect of esketamine in patient-controlled analgaesia after hip replacement on postoperative pain and improve sleep quality in pat...
Psychedelic mushroom-containing chocolate exposures: Case series.
The American journal of emergency medicine – November 01, 2024
Summary
A concerning trend shows teens accessing psychedelics through chocolate edibles. Analysis of 36 cases revealed most patients were around 17 years old who consumed psilocybin-infused candy products. While most experienced temporary effects like altered mental state and hallucinations, some faced more serious symptoms. Though no deaths occurred, this highlights the risks of mushroom-laced chocolate, especially for children.
Abstract
The recreational use of psilocybin or psilocin-containing products, a chemical found naturally in certain mushroom species, is on the rise across t...
Misrepresentation of MDMA in the United States, 1999-2023.
Drug and alcohol dependence – November 01, 2024
Summary
Over half of substances sold as MDMA or Ecstasy contain unexpected ingredients. Drug checking services reveal that while 75% of tested samples were believed to be pure MDMA, only 48% actually were. Quality improved significantly since 2009, with pure MDMA samples rising from 15% to 74% by 2023. Nearly 200 different adulterants were identified, highlighting the importance of drug checking services in promoting safer supply.
Abstract
The misrepresentation of illicit drugs in unregulated markets increases the risk of adverse health events. This study analyzed drug checking data t...
Therapeutic potential of ketamine in management of epilepsy: Clinical implications and mechanistic insights.
Asian journal of psychiatry – November 01, 2024
Summary
Ketamine, traditionally used for anesthesia, shows promising results in controlling seizures when conventional treatments fail. The drug works by restoring balance between excitatory and inhibitory brain signals, making it particularly valuable for drug-resistant epilepsy. Studies reveal it can reduce seizure frequency and protect brain cells, offering hope for the 30% of epilepsy patients who don't respond to standard medications.
Abstract
Epilepsy, a widespread neurological disorder, affects approximately 50 million people worldwide. This disorder is typified by recurring seizures du...
The effect of a subclinical dose of esketamine on depression and pain after cesarean section: A prospective, randomized, double-blinded controlled trial.
Medicine – November 01, 2024
Summary
A single low dose of esketamine after C-section delivery showed promise in reducing post-surgical pain, though it didn't affect postpartum depression rates. In this 150-patient trial, mothers who received esketamine reported significantly less pain for the first 24 hours after surgery compared to those given a placebo. While some temporary side effects occurred, they resolved quickly, suggesting this could be a valuable option for managing post-cesarean discomfort.
Abstract
The aim of this randomized, double-blind placebo-controlled clinical trial was to study the effects of subclinical doses of esketamine on postpartu...
MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.
European child & adolescent psychiatry – November 01, 2024
Summary
MDMA-assisted psychotherapy shows promise for treating PTSD, particularly among adolescents, where existing treatments often fall short. Current evidence indicates that MDMA can enhance therapeutic connections and facilitate trauma processing, potentially benefiting up to 70% of adolescents with PTSD. Adaptations for this age group may include stronger emotional support and family involvement during therapy. While concerns about side effects and misuse exist, targeted clinical trials are essential to assess the safety and efficacy of MDMA-AP for adolescents facing trauma-related challenges.
Abstract
3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may b...
Tags
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Psychopharmacology (Berl) – November 01, 2024
Summary
A significant discovery in MDMA-assisted psychotherapy research explored how discontinuing reuptake inhibitor medications might influence treatment response. Early findings suggested these medication changes could impact positive patient outcomes. However, a subsequent rigorous review of the data identified critical inconsistencies, leading to the withdrawal of the initial conclusions. This highlights the scientific community's dedication to ensuring the highest standards of evidence for effective mental health therapies.
Abstract
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkably, individuals undergoing MDMA-assisted psychotherapy for PTSD experienced sustained symptom relief. Researchers explored if this innovative approach offered lasting benefits. By analyzing data from six prior trials, they tracked participants' progress. The findings consistently showed significant and durable reductions in PTSD symptoms, highlighting the positive and enduring impact of this therapeutic method. This offers compelling evidence for long-term recovery.
Abstract
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 t...
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Nat Med – November 01, 2024
Summary
Many individuals with moderate to severe PTSD experienced significant symptom reduction. A rigorous randomized, placebo-controlled trial investigated if MDMA, paired with therapy, could effectively treat this debilitating condition. Results showed participants receiving MDMA-assisted therapy achieved marked, lasting improvements. This promising approach offers substantial hope for those seeking relief from persistent trauma.
Abstract
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder.
Drugs – November 01, 2024
Summary
Psychedelics may significantly enhance memory processes relevant to posttraumatic stress disorder (PTSD). A review of 25 studies reveals that psychedelics can improve extinction learning, which is often impaired in PTSD. Acute effects were shown to enhance both fear conditioning and semantic memory, potentially aiding in the integration of trauma memories. Although episodic memory formation is negatively impacted, the overall potential of psychedelics in addressing multiple memory mechanisms suggests a promising avenue for refining PTSD therapies. Targeting diverse memory systems could enhance treatment effectiveness.
Abstract
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates ...
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – November 01, 2024
Summary
Brain imaging reveals that depression physically alters synapses - the connection points between brain cells. New technology now allows scientists to measure these changes in living brains using specialized tracers. Lower synaptic density was found in people with depression, but treatments like ketamine can help rebuild these vital connections. This breakthrough helps explain how depression affects the brain and how treatments work.
Abstract
The development of novel radiotracers for Positron Emission Tomography (PET) imaging agents targeting the synaptic vesicle glycoprotein 2 A (SV2A),...
Myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis with super-refractory status epilepticus.
Brain & development – November 01, 2024
Summary
A rare form of autoimmune encephalitis linked to myelin oligodendrocyte glycoprotein can trigger severe, uncontrollable seizures. In a breakthrough case, doctors successfully treated a young patient's resistant seizures using a combination of ketamine infusion and specialized steroid therapy delivered directly to the nervous system. This treatment proved effective when traditional anti-seizure medications failed, offering new hope for managing this challenging condition.
Abstract
Seizures are commonly reported in patients with myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis (MOG-CCE). H...
Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice.
Neuroscience – November 01, 2024
Summary
While psilocybin shows promise for treating various conditions, new research reveals its limitations in addressing cocaine addiction. In controlled experiments, both mice and rats were trained to self-administer cocaine, then given psilocybin during addiction recovery. Despite hopes, the psychedelic compound didn't prevent animals from returning to cocaine-seeking behavior when exposed to familiar drug cues.
Abstract
There are currently no pharmacological treatments for cocaine use disorder. Recently there has been a great deal of interest in the potential of ps...
Psychoactive substances for the treatment of neuropsychiatric disorders.
Asian journal of psychiatry – November 01, 2024
Summary
Groundbreaking treatments using psychedelics are transforming mental healthcare. Ketamine offers rapid relief for severe depression, while MDMA shows remarkable success in treating PTSD. These substances, along with other psychedelics, work by altering brain chemistry and enhancing emotional processing. Clinical trials reveal significant improvements in patients with various neuropsychiatric disorders, often after just a few supervised sessions.
Abstract
In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as ...
Psychoanalysis and psychedelics: The censored story in Argentina.
The International journal on drug policy – November 01, 2024
Summary
In 1950s Argentina, pioneering psychoanalysts explored LSD and other psychedelic drugs as tools to enhance therapeutic breakthroughs. This innovative fusion of psychoanalytic therapy and psychedelics helped patients bypass mental defenses and access deeper psychological insights. Despite promising results, professional resistance in 20th Century Argentine medical circles led to this groundbreaking work being largely forgotten by history.
Abstract
This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, ...
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience
BJPsych Open – November 01, 2024
Summary
Psilocybin, a promising hallucinogen in medicine, can paradoxically trigger severe adverse effects while fostering personal growth. In one clinical psychology case, a participant experienced increased suicidal ideation and restricted eating after psilocybin administration for depression. Despite these challenges and limited improvement on quantitative scales, a thematic analysis of her account revealed the experience led to beneficial life changes. This highlights the complex psychological impact of psilocybin, suggesting its use in psychiatry requires careful qualitative assessment beyond standard measures.
Abstract
Background Psilocybin is being investigated as a treatment for a myriad of disorders, including treatment-resistant depression. The main focus has ...
Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action
Current Psychiatry Reports – November 01, 2024
Summary
Severe insomnia and sleep disturbances can hinder psilocybin's antidepressant effects in treating major depressive disorder. While clinical trials demonstrate large improvements in depressive symptoms, psilocybin's direct impact on sleep quality has been less explored in psychology and psychiatry. Preliminary clinical psychology data suggests both depression and sleep issues decrease after psilocybin use, though sleep improvements are smaller. This highlights a critical intersection for mental health research topics and medicine. Addressing sleep, perhaps related to tryptophan pathways, could optimize psychedelic-assisted therapy, leading to more effective strategies in drug studies and clinical trials for depression.
Abstract
Abstract Purpose of the study Psilocybin is a rapidly-emerging treatment for depression, yet its impact on sleep is not well understood. We sought ...
FDA Denies Approval of MDMA-Assisted Therapy for PTSD
AJN, American Journal of Nursing – November 01, 2024
Summary
For many battling PTSD, standard therapies fall short. New research explored MDMA-assisted therapy, revealing significant symptom reduction for participants. Despite these positive outcomes, the treatment was not approved, with the agency citing potential dangers and methodological flaws in its development.
Abstract
The agency cited potential dangers and flaws in research methodology.
Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland
Consciousness, Spirituality & Transpersonal Psychology – October 31, 2024
Summary
Scottish psychiatry trainees show surprising openness to psychedelic-assisted therapy and mystical experiences in mental health treatment. Through interviews, researchers found doctors were receptive to incorporating these novel approaches while maintaining medical rigor. They recognized both therapeutic potential and need for proper training, suggesting a possible bridge between traditional psychiatry and transformative treatment methods.
Abstract
Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictio...
Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis.
CNS spectrums – October 31, 2024
Summary
Breakthrough findings show esketamine significantly reduces postpartum depression (PPD) risk. This nasal spray treatment, already proven effective for treatment-resistant depression, cut PPD rates by 70% when given during childbirth. The medication helps prevent major depressive disorder in new mothers, with benefits lasting up to 6 weeks after delivery, offering new hope for perinatal depression management.
Abstract
Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related qua...
Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials
Journal of Psychopharmacology – October 31, 2024
Summary
Psilocybin, a classic hallucinogen, significantly reduces depression symptoms. A systematic review and meta-analysis of clinical trials, sourced from MEDLINE and Cochrane Library, revealed a large, clinically observable reduction (SMC: -1.24) in depressive symptomatology compared to placebo. This serotonergic medicine, a chemically synthesized alkaloid, shows promise in psychiatry and clinical psychology. Its influence on neurotransmitter receptors offers a novel approach for mental health, outperforming traditional treatments for depression.
Abstract
Background: Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approac...
A narrative exploration of psilocybin’s potential in mental health
Frontiers in Psychiatry – October 30, 2024
Summary
Psilocybin, a potent hallucinogen, is demonstrating high therapeutic potential in psychiatry. This review explores its chemical synthesis and alkaloid properties, alongside how its influence on neurotransmitter receptors impacts behavior, offering promise for various mental health disorders. Accumulating clinical evidence supports its benefits, moving this psychedelic into mainstream medicine. While generally safe, careful dosing and psychotherapist-led distress management are crucial. This burgeoning field of Psychedelics and Drug Studies aims to integrate psilocybin into psychology and psychiatric treatments, paving the way for its wider acceptance.
Abstract
Psilocybin, a psychoactive substance, has recently garnered attention for its high therapeutic potential in psychiatry. In this study, we investiga...
Efficacy and safety of esketamine combined with propofol for conscious sedation in painless colonoscopy: a prospective, randomized, double-blind controlled clinical trial.
BMC anesthesiology – October 30, 2024
Summary
A breakthrough in colonoscopy comfort: combining esketamine with propofol for conscious sedation proves safer than traditional deep sedation. This approach reduces risks of oxygen drops and blood pressure issues while maintaining high patient satisfaction. The technique offers faster recovery times and fewer side effects, making painless colonoscopy procedures more comfortable and efficient.
Abstract
We explored the efficacy and safety of esketamine combined with propofol for conscious sedation in painless colonoscopy. A total of 195 patients wh...
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.
J Psychoactive Drugs – October 30, 2024
Summary
Remarkably, positive psychedelic experiences can profoundly shift negative thought patterns. Research explored how the immediate reactions during these experiences relate to subsequent changes in negative thinking and overall wellbeing. By analyzing participants' self-reported data, it was found that positive acute reactions were strongly linked to significant reductions in negative thinking and enhanced wellbeing. This suggests these unique psychedelic experiences can foster lasting improvements in mental health.
Abstract
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.
Differentiation of Ayahuasca Samples According to Preparation Mode and Botanical Varieties Using Metabolomics.
Journal of psychoactive drugs – October 29, 2024
Summary
Traditional ayahuasca brews, made from Banisteriopsis caapi vines and other plants, show remarkable variation in their chemical makeup based on preparation methods. Using advanced metabolomics and mass spectrometry, researchers analyzed 126 samples from different religious groups, finding distinct chemical profiles and antioxidant properties linked to specific preparation techniques.
Abstract
Ayahuasca is a brew traditionally prepared with a mixture of Psychotria viridis leaves and Banisteriopsis caapi vine and has demonstrated therapeut...
“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin
Journal of Psychedelic Studies – October 29, 2024
Summary
For mental health, whole Psilocybe mushrooms and their extracts offer a more natural and superior experience than synthetic psilocybin. Participants in a Psilocybin-Assisted Therapy program for end-of-life distress reported that while synthetic psilocybin, whole *Psilocybe cubensis*, and mycological extract all provided emotional insight and mystical experiences, synthetic psilocybin felt less natural and had an inferior overall quality. This suggests future Psychedelics and Drug Studies in psychology and psychiatry should prioritize natural mushroom compounds in medicine, moving beyond synthetic drug forms.
Abstract
Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such...
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
J Psychopharmacol – October 29, 2024
Summary
As psychedelic therapy gains momentum in mental health treatment, understanding its risks is crucial. This comprehensive analysis examines adverse events during psychedelic-assisted therapy, from mild anxiety to rare psychological challenges. While most sessions prove safe under proper supervision, the review identifies key factors for minimizing risks: careful patient screening, therapist training, and structured support systems during sessions.
Abstract
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
Yangonin, one of the kavalactones isolated from Piper methysticum G. Forst, acts through cannabinoid 1 (CB1) receptors to induce an intrathecal anti-hyperalgesia.
Journal of ethnopharmacology – October 28, 2024
Summary
Yangonin, a kavalactone from the kava plant, shows significant promise as a pain reliever. In tests with male Sprague-Dawley rats, yangonin (19.36 nmol/rat) effectively reduced inflammatory hyperalgesia induced by carrageenan, while kavain (27.14 nmol/rat) showed no impact on pain responses. The anti-nociceptive effects of yangonin were reversed when a cannabinoid 1 (CB1) receptor antagonist was co-administered, highlighting its mechanism. This suggests that yangonin could be a valuable treatment option for managing pain through its action on CB1 receptors.
Abstract
Piper methysticum G. Forst (Piperaceae) is traditionally consumed in Polynesian culture. The roots are used to produce an entheogenic drink and tra...
Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner
Molecules – October 28, 2024
Summary
A compelling finding: Psilocybin's active metabolite, psilocin, a hallucinogen, shows significant potential in modulating brain inflammation. In pharmacology and neuroscience, experiments on microglia-like cells revealed this chemistry, acting on specific receptors, inhibited their phagocytic activity and reduced reactive oxygen species and nitric oxide production. This neurotransmitter receptor influence on behavior is crucial. These drug studies, involving psychedelics and chemical synthesis of alkaloids, suggest psilocin could treat neurodegenerative conditions, offering new avenues in psychology and medicine.
Abstract
Neuroinflammation that is caused by microglia, the main immune cells of the brain, contributes to neurodegenerative diseases. Psychedelics, includi...
Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.
European archives of psychiatry and clinical neuroscience – October 28, 2024
Summary
Ketamine's ability to induce altered states of consciousness may be key to its remarkable antidepressant effects. Half of analyzed studies found that ketamine's psychedelic and dissociative effects positively influenced treatment outcomes for depression, anxiety, and substance dependence. The strongest benefits appeared in treating addiction, while results varied for mood disorders. IV administration showed more promise than other methods.
Abstract
This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psyc...
Ketamine and chronic treatment-resistant depression: real-world practice and after relapse.
BMC psychiatry – October 28, 2024
Summary
Ketamine shows promise as a rapid-acting treatment for chronic treatment-resistant depression (TRD), but its effects require careful management. In real-world clinical practice, patients receiving six ketamine infusions showed significant improvement, with 67% responding positively to treatment. While the antidepressant effect was notable, symptoms typically returned after relapse. MADRS scores helped track patient progress, suggesting ketamine may work best as an adjuvant therapy alongside other treatments.
Abstract
Chronic treatment-resistant depression (TRD) poses a major challenge for clinicians. Ketamine has shown a rapid but short-lived antidepressant effe...
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.
British journal of pharmacology – October 28, 2024
Summary
Psychedelic drugs may offer rapid relief for depression, with early trials showing significant promise. In animal studies, specific behaviors linked to these drugs reveal potential antidepressant effects. For instance, using clinically relevant doses can enhance understanding of how these substances work. With a focus on 100+ preclinical studies and attention to sex differences, researchers are unraveling the neuropsychological mechanisms behind psychedelics. This knowledge could pave the way for new treatments and drug targets, advancing mental health care significantly.
Abstract
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid-acting antidepressants (...
Advancing ketamine in the treatment hierarchy for refractory depression.
The British journal of psychiatry : the journal of mental science – October 25, 2024
Summary
Ketamine shows promise as an earlier treatment option for people with hard-to-treat depressive disorders. Research reveals it works faster than traditional antidepressants and has fewer side effects. When integrated into general adult psychiatry practice, this psychopharmacology approach could significantly improve patients' quality of life before their condition becomes severe.
Abstract
Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strateg...
Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada
PLoS ONE – October 24, 2024
Summary
Psychedelic clinics in Ontario are promoting psilocybin and other psychedelics for an astonishing 47 distinct medical conditions, often with insufficient scientific backing. An analysis of 10 clinic websites revealed only 2 out of 10 described potential risks. While 29 studies were cited for these medical prescriptions, most offered low-to-moderate "level 4" evidence, like case-series. This raises concerns for mental health patients seeking medicine, underscoring the need for transparent, high-quality information regarding psychedelic treatments in family medicine and psychiatry.
Abstract
Psychedelics, including ketamine, 3,4-Methyl enedioxy methamphetamine (MDMA), and psilocybin, have gained attention for their potential therapeutic...
Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis
FEBS Letters – October 24, 2024
Summary
Psilocybin, a natural hallucinogen, shows immense promise in Psychedelics and Drug Studies for mental health. Its biosynthesis involves a crucial Kinase enzyme, PsiK, catalyzing phosphorylation. Through detailed Biochemistry, including crystallographic analysis and mutagenesis, its substrate recognition chemistry is now precisely understood. This fundamental chemical insight supports future chemical synthesis and alkaloids research, enabling bioengineering of enhanced psilocybin variants. Such enzyme studies broadly inform drug development, from psychedelics to compounds like Phenothiazines and Benzothiazines Synthesis and Activities.
Abstract
Psilocybin, the natural hallucinogen from Psilocybe (magic) mushrooms, is a highly promising drug candidate for the treatment of depression and sev...
Effect of different doses of esketamine on the median effective concentration of propofol for inhibiting body movement during hysteroscopy.
Scientific reports – October 24, 2024
Summary
Combining anesthetics strategically can lead to better patient outcomes. When esketamine is paired with propofol during hysteroscopy procedures, doctors can use less propofol while still effectively preventing patient movement. Higher doses of esketamine (0.3 mg/kg) allowed for a 20% reduction in required propofol levels, while also reducing post-operative anxiety and depression scores.
Abstract
The objective of this study is to investigate the effects of various doses of esketamine on the median effective concentration (EC50) of propofol r...
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
BMC Medical Education – October 24, 2024
Summary
Australia has already approved MDMA and psilocybin for mental health, highlighting Europe's urgent need to advance medical education in psychedelic-assisted therapy. With USA trials in Phase III, Germany is poised to lead Europe in developing robust frameworks for integrating innovative Psychedelics and Drug Studies into Medicine. This includes defining ethical Psychotherapy Techniques and Applications, practitioner training, and regulatory oversight. Such infrastructure development aims to ensure proficient care, potentially reclaiming Europe's historical lead in Psychology and psychiatric innovation, as seen with Switzerland's 2014 reintroduction of MDMA and LSD for restricted medical use.
Abstract
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psyche...
Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour
OpenAlex – October 24, 2024
Summary
A single 1 mg/kg dose of Psilocybin dramatically reduced obsessive compulsive-like behaviors for up to a week in male knockout mice, a key model in Psychology for compulsive disorders. This finding, from Drug Studies involving male and female mice, suggests new ways psychedelics influence behavior by impacting neurotransmitter receptors. It also reduced grooming in female mice. This research, advancing our understanding of brain function and potential therapeutic technology, offers promise for developing novel treatments for compulsive conditions, moving beyond current options.
Abstract
Abstract Psilocybin is a serotonergic psychedelic compound which shows promise for treating compulsive behaviours. This is particularly pertinent a...
How Bud Craig's Insights Reshape the Research on Pain and Mind-Body Therapies.
Current topics in behavioral neurosciences – October 23, 2024
Summary
Bud Craig's innovative work redefined pain as a homeostatic emotion, linking it to interoception—the brain's ability to perceive internal bodily states. His findings, based on extensive studies, highlight that mind-body therapies like mindfulness, meditation, and yoga are essential non-drug treatments for chronic pain management. With a focus on interoceptive processes, his research supports that these therapies can significantly improve emotional and physical well-being. This framework has shaped contemporary approaches in clinical settings, influencing how pain is understood and treated across various conditions.
Abstract
With his elegant studies, Bud Craig determined the structural neural basis for interoception and critically expanded our conceptual understanding o...
Neural Correlates of Psychedelic, Sleep, and Sedated States Support Global Theories of Consciousness.
bioRxiv : the preprint server for biology – October 23, 2024
Summary
Psychedelics significantly enhance global functional connectivity while reducing local neural synchrony, revealing a compelling link between brain network interactions and consciousness. An analysis using fMRI data from 150 participants across various states—psychedelics, sleep, and deep sedation—showed that psychedelic experiences are characterized by increased connectivity in anterior-posterior regions. In contrast, non-REM sleep and deep sedation exhibited decreased global integration. These findings suggest that consciousness emerges from widespread brain interactions rather than localized activity, bridging two major theories: Global Neuronal Workspace and Integrated Information Theory.
Abstract
Understanding neural mechanisms of consciousness remains a challenging question in neuroscience. A central debate in the field concerns whether con...
Ayahuasca drinking using a two-bottle choice procedure in male mice.
Scientific reports – October 23, 2024
Summary
Male mice given a choice between water and Ayahuasca showed fascinating drinking patterns: frequent access led to preference for the psychedelic brew, while longer breaks between drinks resulted in aversion. Using a two-bottle choice setup, researchers found that concentration matters - mice preferred lower doses when offered regularly but avoided higher doses when given less frequently.
Abstract
Ayahuasca has been proposed as a treatment for substance use disorders. However, because of its hallucinogenic properties, studies investigating it...